JP6875274B6 - ピチンデウイルスのリバースジェネティクス系及び使用方法 - Google Patents

ピチンデウイルスのリバースジェネティクス系及び使用方法 Download PDF

Info

Publication number
JP6875274B6
JP6875274B6 JP2017515764A JP2017515764A JP6875274B6 JP 6875274 B6 JP6875274 B6 JP 6875274B6 JP 2017515764 A JP2017515764 A JP 2017515764A JP 2017515764 A JP2017515764 A JP 2017515764A JP 6875274 B6 JP6875274 B6 JP 6875274B6
Authority
JP
Japan
Prior art keywords
protein
virus
coding region
genomic segment
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017515764A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017529084A5 (https=
JP6875274B2 (ja
JP2017529084A (ja
Inventor
ヒン リー，
ヒン リー，
ユーイン リャン，
ユーイン リャン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Minnesota Twin Cities
Original Assignee
University of Minnesota System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Minnesota System filed Critical University of Minnesota System
Publication of JP2017529084A publication Critical patent/JP2017529084A/ja
Publication of JP2017529084A5 publication Critical patent/JP2017529084A5/ja
Publication of JP6875274B2 publication Critical patent/JP6875274B2/ja
Application granted granted Critical
Publication of JP6875274B6 publication Critical patent/JP6875274B6/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2760/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2017515764A 2014-09-22 2015-09-22 ピチンデウイルスのリバースジェネティクス系及び使用方法 Active JP6875274B6 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462053443P 2014-09-22 2014-09-22
US62/053,443 2014-09-22
PCT/US2015/051337 WO2016048949A1 (en) 2014-09-22 2015-09-22 Pichinde virus reverse genetics system and methods of use

Publications (4)

Publication Number Publication Date
JP2017529084A JP2017529084A (ja) 2017-10-05
JP2017529084A5 JP2017529084A5 (https=) 2021-05-06
JP6875274B2 JP6875274B2 (ja) 2021-05-19
JP6875274B6 true JP6875274B6 (ja) 2021-06-30

Family

ID=54238628

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017515764A Active JP6875274B6 (ja) 2014-09-22 2015-09-22 ピチンデウイルスのリバースジェネティクス系及び使用方法

Country Status (12)

Country Link
US (2) US10533159B2 (https=)
EP (1) EP3198008B1 (https=)
JP (1) JP6875274B6 (https=)
KR (1) KR20170057384A (https=)
CN (1) CN107109371A (https=)
AU (1) AU2015321557B2 (https=)
BR (1) BR112017005744B1 (https=)
CA (1) CA2961913A1 (https=)
ES (1) ES2746150T3 (https=)
MX (1) MX391006B (https=)
PL (1) PL3198008T3 (https=)
WO (1) WO2016048949A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107109371A (zh) 2014-09-22 2017-08-29 明尼苏达大学评议会 皮钦德病毒反向遗传学系统及其使用方法
SI3218504T1 (sl) * 2014-11-13 2020-11-30 Universite De Geneve Tri-segmentirani arenavirusi kot vakcinski vektorji
AU2016274655B2 (en) 2015-06-10 2021-06-17 NeoTrail Therapeutics, Inc. HPV vaccines
CA3003557A1 (en) 2015-11-04 2017-05-11 Hookipa Biotech Ag Vaccines against hepatitis b virus
DK3373959T3 (da) 2015-11-12 2022-09-19 Hookipa Biotech Gmbh Arenaviruspartikler som cancervacciner
IL262963B2 (en) * 2016-05-18 2025-01-01 Hookipa Biotech Gmbh Trisegmented PICHINDE viruses as vaccine vectors
US20230310574A1 (en) * 2020-08-06 2023-10-05 Regents Of The University Of Minnesota Multivalent vaccines against turkey arthritis reovirus
WO2022269362A2 (en) 2021-06-21 2022-12-29 Vaxxinova International B.V. Veterinary viral vector
WO2024155646A1 (en) * 2023-01-17 2024-07-25 Regents Of The University Of Minnesota Multivalent vaccines against tuberculosis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2170622B1 (es) 1999-12-03 2004-05-16 Consejo Superior De Investigaciones Cientificas Clones y vectores infectivos derivados de coronavirus y sus aplicaciones.
ES2424214T3 (es) 2007-08-27 2013-09-30 Siga Technologies, Inc. Medicamentos antivirales para el tratamiento de una infección por Arenavirus
AP3126A (en) 2007-12-21 2015-02-28 Government Of The Us Secretary Recombinant rift valley fever (RVF) viruses and methods of use
SI2604695T1 (sl) * 2007-12-27 2023-03-31 Universitaet Zuerich Prorektorat Forschung Replikacijsko defektni arenavirusni vektorji
EP2478103A4 (en) 2009-09-16 2014-02-19 Univ Tulane LASSAVIRUS-like PARTICLES AND METHOD FOR THE PRODUCTION THEREOF
GB201007790D0 (en) 2010-05-10 2010-06-23 Isis Innovation Compositions
JP2013531496A (ja) 2010-06-06 2013-08-08 モウント シナイ スクール オフ メディシネ 組換えｒｎａウイルス及びその使用
CN107109371A (zh) 2014-09-22 2017-08-29 明尼苏达大学评议会 皮钦德病毒反向遗传学系统及其使用方法

Also Published As

Publication number Publication date
KR20170057384A (ko) 2017-05-24
PL3198008T3 (pl) 2020-03-31
EP3198008B1 (en) 2019-05-29
ES2746150T3 (es) 2020-03-04
WO2016048949A1 (en) 2016-03-31
BR112017005744B1 (pt) 2023-11-28
US11993789B2 (en) 2024-05-28
BR112017005744A2 (pt) 2017-12-12
CN107109371A (zh) 2017-08-29
US20200165578A1 (en) 2020-05-28
AU2015321557B2 (en) 2020-05-14
US20170292119A1 (en) 2017-10-12
AU2015321557A1 (en) 2017-04-06
MX391006B (es) 2025-03-21
JP6875274B2 (ja) 2021-05-19
EP3198008A1 (en) 2017-08-02
CA2961913A1 (en) 2016-03-31
JP2017529084A (ja) 2017-10-05
US10533159B2 (en) 2020-01-14
MX2017003694A (es) 2017-10-12

Similar Documents

Publication Publication Date Title
JP6875274B6 (ja) ピチンデウイルスのリバースジェネティクス系及び使用方法
JP2017529084A5 (https=)
US10494613B2 (en) Generation of infectious influenza viruses from virus-like particles
CN101903043B (zh) 经过修饰的流感病毒
EP3022298B1 (en) Attenuated influenza vaccines and uses thereof
KR20180067464A (ko) 감염성 질환의 예방 및/또는 치료와 종양학적 질환의 치료를 위한 약독화된 인플루엔자 벡터
CN107208071A (zh) 用于流感病毒的减弱活疫苗
JP2023532735A (ja) 組み換えエンテロウイルスおよびその使用
KR101908905B1 (ko) 인플루엔자 바이러스의 h9 및 h5의 다중 아형에 대한 교차 면역반응을 형성하는 신규한 재조합 인플루엔자 바이러스 및 이를 포함하는 백신
US10323231B2 (en) Attenuated influenza vaccines and uses thereof
KR101582490B1 (ko) 인플루엔자 바이러스의 다중 아형에 대한 교차 면역반응을 형성하는 신규한 재조합 바이러스 백신
US20240285748A1 (en) Veterinary viral vector
US10272149B2 (en) Modified bat influenza viruses and their uses
US20230310574A1 (en) Multivalent vaccines against turkey arthritis reovirus
US12582708B2 (en) Recombinant influenza viruses comprising truncated NS1 fusion proteins
Amara Old, Running and Future Vaccines: Where are we

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180921

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180921

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191023

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200422

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200929

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210225

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20210326

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210413

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210422

R150 Certificate of patent or registration of utility model

Ref document number: 6875274

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250